| Biomarker ID | 1830 |
| PMID | 30616540 |
| Year | 2019 |
| Biomarker | E2F2 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 2.84 (95% CI: 0.715–11.309) |
| Effect on Pathways | Pathways include: Pathways in cancer, Cell cycle, TGF-beta regulation of extracellular matrix, Interleukin-2 signaling pathway, Cyclin D-associated events in G1 |
| Experiment | Biochemical Recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 158 patients from TCGA were taken into account for this study who had Gleason Score 7. 13 patients experienced Biochemical Recurrence |
| Senstivity | 77% |
| Specificity | 63% |
| AUC | 0.682 |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |